NPPB and cancer: These measures in conjunction with cardiac biomarkers allow grading severity of cancer therapy-related cardiac dysfunction (CTRCD) into “mild,” “moderate,” and “severe” (e.g., mild CTRCD is defined as an LVEF ≥ 50% AND new relative decline in global longitudinal strain (GLS) by > 15% from baseline AND/OR new rise in cardiac biomarkers (troponin I/T > 99th percentile, BNP ≥ 35 pg/ml, NT-proBNP ≥ 125 pg/ml, Table 2) [16].